Edward A Byrd

US Patent:

6572888, Jun 3, 2003

Filed:

Jan 5, 2001

Appl. No.:

09/755890

Inventors:

Edward A. Byrd - San Francisco CA

Assignee:

Medical Research Institute - San Bruno CA

International Classification:

A61K 922

US Classification:

424468, 424451, 424452, 424457, 424463, 424464, 424465, 424474, 424475, 424489, 424490, 424400

Abstract:

A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.

US Patent:

6905707, Jun 14, 2005

Filed:

Aug 23, 2002

Appl. No.:

10/226646

Inventors:

Edward A. Byrd - San Francisco CA, US

Assignee:

Medical Research Institute - San Francisco CA

International Classification:

A61K009/20
A61K009/22
A61K031/195
A61K031/205

US Classification:

424468, 424464, 424465, 514557, 514561

Abstract:

An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e. g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.

US Patent:

7118762, Oct 10, 2006

Filed:

Apr 11, 2003

Appl. No.:

10/412559

Inventors:

Edward A. Byrd - San Francisco CA, US

Assignee:

Medical Research Institute - San Francisco CA

International Classification:

A61K 9/22
A61K 9/48
A61K 9/00
A61K 9/28
A61K 9/14

US Classification:

424468, 424451, 424452, 424457, 424463, 424464, 424465, 424474, 424475, 424489, 424490, 424400

Abstract:

A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.

US Patent:

7579020, Aug 25, 2009

Filed:

Dec 30, 2004

Appl. No.:

11/026430

Inventors:

Edward A. Byrd - San Francisco CA, US

Assignee:

Medical Research Institute - San Francisco CA

International Classification:

A61K 9/20
A61K 9/22
A61K 31/195

US Classification:

424468, 424451, 424464, 424489, 514557, 514561

Abstract:

An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e. g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.

US Patent:

20040259895, Dec 23, 2004

Filed:

Oct 23, 2003

Appl. No.:

10/693837

Inventors:

Edward Byrd - San Francisco CA, US

Assignee:

Medical Research Institute

International Classification:

A61K031/51
A61K031/385

US Classification:

514/276000, 514/440000

Abstract:

A biphasic formulation of lipid soluble thiamine and lipoic acid for oral administration is disclosed. The lipoic acid and lipid soluble thiamine are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation following by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.

US Patent:

20050085498, Apr 21, 2005

Filed:

Sep 21, 2004

Appl. No.:

10/947054

Inventors:

Edward Byrd - San Francisco CA, US

International Classification:

A61K031/555
A61K031/385
A61K031/198

US Classification:

514275000, 514440000, 514563000, 514565000

Abstract:

A formulation comprised of four active components which are a lipid soluble thiamine, lipoic acid, arginine α-ketoglutarate, and a creatine derivative for oral administration is disclosed. The active components may be combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation following by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to obtain a range of beneficial effects including reducing serum glucose levels and maintaining those reduced glucose levels over time to treat diabetic polyneuropathy as well as improving circulation and increasing muscle performance.

US Patent:

20060024367, Feb 2, 2006

Filed:

Aug 8, 2005

Appl. No.:

11/199919

Inventors:

Edward Byrd - San Francisco CA, US

International Classification:

A61K 9/22
A61K 31/704
A61K 31/663
A61K 31/385

US Classification:

424468000, 514025000, 514102000, 514440000

Abstract:

A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation followed by a gradual release of any remaining active ingredients in a manner which makes it possible to (1) quickly obtain a therapeutic level of the active ingredients; and (2) substantially increase the period of time over which therapeutic levels of the active ingredients are maintained relative to a quick release formulation. These features make it possible to use the formulation to reduce serum glucose levels and maintain those reduced glucose levels over time to treat diabetic polyneuropathy and thereby obtaining a range of desired therapeutic results.

US Patent:

20060062849, Mar 23, 2006

Filed:

Sep 21, 2004

Appl. No.:

10/947058

Inventors:

Edward Byrd - San Francisco CA, US

International Classification:

A61K 9/22
A61K 31/22

US Classification:

424468000, 514551000

Abstract:

Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt of a stearate, e.g. magnesium stearates. The formulation is produced as flowable particles with a sieve size of about 20 to 60 which particles are coated with a shellac to mask taste, avoid moisture uptake, and extend shelf life.